If you are:
FDB Only When Necessary: RISK OF NEONATAL WITHDRAWAL SYNDROME WITH CHRONIC USE
FDB Contraindicated or Not Recommended: PREMATURE CLOSURE OF DUCTUS ARTERIOSUS, AVOID DURING 3RD TRIMESTER
Precaution: MONITOR FOR CHANGES IN RESPIRATION, GI EFFECTS, SEDATION, FEEDING PATTERN
No Known Risk: LOW LEVELS IN BREAST MILK, WITH NO KNOWN RESULTING ADVERSE EFFECT ON INFANT
An adult over 60:
management or monitoring precaution: Pulmonary-Life threatening respiratory depression is more likely to occur with high doses, SR products, cachexia, or debilitation due to altered pharmacokinetics with poor fat stores, muscle wasting, or altered clearance. Monitor closely at initiation and with dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.
management or monitoring precaution: Gastrointestinal-Risk for ulceration or serious GI bleed; highest with history of PUD or GI bleed. Renal-Risk for exacerbation of CKD. Cardiovascular-May exacerbate pre-existing hypertension or CHF. Risk of cardiovascular thrombotic events, including MI and stroke. This risk may occur early in treatment and increases with duration of use. Risk for reinfarction with minimal NSAID use post-MI. Contraindicated with CABG. Hepatic-Elevated hepatic transaminases may occur with chronic use.
Giving OXYCODONE HCL-IBUPROFEN to a child under 12:
Severe Precaution: Risk of respiratory and CNS depression. No safety and efficacy.
Severe Precaution: Potential increased sensitivity to effects, adverse CNS effects and respiratory depression.
management or monitoring precaution: Safety and efficacy for children less than 6 months not established.